Water management company Northwest Pipe (NASDAQ:NWPX) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 8.6% year on year to $119.6 million. Its GAAP profit of $1 per share was 9.5% above analysts’ consensus estimates.
Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 6% year on year to $79.61 million. On the other hand, next quarter’s revenue guidance of $79 million was less impressive, coming in 3.5% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was 47.6% below analysts’ consensus estimates.
Salesforce's outlook fell short of analysts’ expectations, sending shares lower in extended trading Wednesday.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 8.2% above analysts’ estimates. Its GAAP profit of $0.26 per share was 39% below analysts’ consensus estimates.
Leading edge card issuer Marqeta (NASDAQ: MQ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.3% year on year to $135.8 million. Guidance for next quarter’s revenue was better than expected at $135.7 million at the midpoint, 1.7% above analysts’ estimates. Its GAAP loss of $0.05 per share was in line with analysts’ consensus estimates.
Energy recovery device manufacturer Energy Recovery (NASDAQ:ERII) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 17.3% year on year to $67.08 million. Its non-GAAP profit of $0.50 per share was 24% above analysts’ consensus estimates.
Burger restaurant chain Red Robin (NASDAQ:RRGB) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 7.7% year on year to $285.2 million. On the other hand, the company’s full-year revenue guidance of $1.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP loss of $0.94 per share was 63.8% below analysts’ consensus estimates.
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was 7.8% below analysts’ consensus estimates.
Online marketplace eBay (NASDAQ:EBAY) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.58 billion. On the other hand, next quarter’s revenue guidance of $2.54 billion was less impressive, coming in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.25 per share was 4.3% above analysts’ consensus estimates.
Leading designer of graphics chips Nvidia (NASDAQ:NVDA) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 77.9% year on year to $39.33 billion. Guidance for next quarter’s revenue was optimistic at $43 billion at the midpoint, 2.1% above analysts’ estimates. Its non-GAAP profit of $0.89 per share was 5.2% above analysts’ consensus estimates.
